Gilead Sciences ((GILD)), Gilead Sciences (($CC:GILD.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Gilead Sciences is currently recruiting participants for a pivotal Phase 3 clinical study titled ‘A Global, Multicenter, Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Standard of Care (SOC) in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer (ES-SCLC)’. The study aims to evaluate the efficacy of sacituzumab govitecan (SG) compared to standard treatments in improving the objective response rate and overall survival in patients with ES-SCLC.
The intervention being tested is sacituzumab govitecan, an intravenous drug administered to participants in the experimental group. It is compared against standard care options such as Topotecan and Amrubicin (in Japan), which are also administered intravenously.
This study employs a randomized, parallel intervention model without masking, focusing primarily on treatment. Participants are allocated to either the experimental group receiving SG or the control group receiving standard care.
The study officially began on April 4, 2025, with its primary completion and estimated completion dates yet to be announced. The latest update was submitted on August 8, 2025, indicating ongoing recruitment and study progress.
For investors, the outcome of this study could significantly impact Gilead Sciences’ market position, especially if SG demonstrates superior efficacy. Positive results could enhance investor confidence and potentially boost Gilead’s stock performance, while also positioning the company competitively within the oncology market.
The study is ongoing, with further details available on the ClinicalTrials portal.